Immune Interactions with Islet Cells: Implications for the Pathogenesis of Insulin-Dependent Diabetes Mellitus

  • J. Nerup
  • T. Mandrup-PouIsen
  • J. Mølvig
  • G. Spinas

Abstract

Occasionally a single scientific paper may signal a new era in the study of a disease. The 1965 paper by Willy Gepts was such a signal [1]. The (re)discovery of insulitis provided the impetus for new thoughts about the pathogenesis of insulin-dependent diabetes mellitus (IDDM) and for the emergence of a new research field: immunology of IDDM.

Keywords

Toxicity Amide Superoxide Nicotin Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gepts W (1965) Pathological anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14: 619–633PubMedGoogle Scholar
  2. 2.
    Gepts W (1983) Role of cellular immunity in the pathogenesis of type 1 diabetes. Curr Probl Clin Biochem 12: 86–99PubMedGoogle Scholar
  3. 3.
    Gepts W, LeCompte PM (1985). The pathology of type 1 (juvenile) diabetes. In: Volk BW, Arquilla ER (eds) The diabetic pancreas. Plenum, New York, pp 337–365Google Scholar
  4. 4.
    Junker K, Egeberg J, Kromann H, Nerup J (1977) An autopsy study of the islets of Langerhans in acute-onset juvenile diabetes mellitus. Acta Pathol Microbiol Scand (Sect A) 85: 699–706Google Scholar
  5. 5.
    Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PGF, Gamble DR (1985) In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313: 353–360PubMedCrossRefGoogle Scholar
  6. 6.
    Foulis AK, Farquharson MA (1982) Aberrant expression of HLA-DR antigens by insulin-containing ß-cells in recent-onset Type I diabetes mellitus. Diabetes 35:1215–1224CrossRefGoogle Scholar
  7. 7.
    Sibley RK, Sutherland DER, Goetz F, Michael AF (1985) Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53:132–144PubMedGoogle Scholar
  8. 8.
    Kolb-Bachofen V, Kolb H (1983) New concept of insulitis and B-islet cell destruction. Diabetes 32 [suppl 1]: 22AGoogle Scholar
  9. 9.
    Kolb H, Kantwerk G, Treichel U, Kürner T, Kiesel U, Hoppe T, Kolb-Bachofen V (1986) Prospective analysis of islet lesions in BB rats. Diabetologia 29: 559AGoogle Scholar
  10. 10.
    Dean BM, Walker R, Bone AJ, Baird JD, Cooke A (1985) Pre-diabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of rat MHC class II molecules in endocrine cells. Diabetologia 28: 464–466PubMedCrossRefGoogle Scholar
  11. 11.
    Nerup J, Andersen OO, Bendixen G, Egeberg J, Poulsen JE (1971) Antipancreatic cellular hypersensitivity in diabetes mellitus. Diabetes 20: 424–427PubMedGoogle Scholar
  12. 12.
    Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiences. Lancet II: 1279–1282CrossRefGoogle Scholar
  13. 13.
    Lernmark Å, Freedman ZR, Hofman C, Rubinstein AH, Steiner DF, Jackson RL, Winter RJ, Traisman HS (1978) Islet-cell-surface antibodies in juvenile diabetes mellitus. N Engl J Med 299:375–380PubMedCrossRefGoogle Scholar
  14. 14.
    Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark Å (1982) Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298:167–169PubMedCrossRefGoogle Scholar
  15. 15.
    MacCuish AC, Irvine WJ (1975) Autoimmunological aspects of diabetes mellitus. Clin Endocrinol Metab 4: 434–471CrossRefGoogle Scholar
  16. 16.
    Maron R, Elias D, de Jongh BM, Braining GJ, van Rood JJ, Shechter Y, Cohen IR (1983) Autoantibodies to the insulin receptor in juvenile onset insulin-dependent diabetes. Nature 303:817–818PubMedCrossRefGoogle Scholar
  17. 17.
    Huang S-W, Haedt LH, Rich S, Barbosa J (1981) Prevalence of antibodies to nucleic acids in insulin-dependent diabetics and their relatives. Diabetes 30: 873–874PubMedGoogle Scholar
  18. 18.
    Irvine WJ, Al-Khateeb SF, DiMario U, Feek CM, Gray RS, Edmond B, Duncan UP (1977) Soluble immune complexes in the sera of newly diagnosed insulin-dependent diabetics and in treated diabetics. Clin Exp Immunol 30:16–21PubMedGoogle Scholar
  19. 19.
    Papadopoulos G, Petersen J, Andersen V, Lernmark Å, Marner B, Nerup J, Binder J (1984) Spontaneous in vitro immunoglobulin secretion at the diagnosis of insulin-dependent diabetes. Acta Endocrinol 105: 521–527PubMedGoogle Scholar
  20. 20.
    Scott J, Nerup J, Lernmark Å (1985) Immunologic factors in diabetes mellitus. In: Rosse WF (ed) Clinical immunology. Update reviews for physicians. Elsevier, Amsterdam, 53–85Google Scholar
  21. 21.
    Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, Cudworth AG (1981) Evidence for a long prediabetic period in type 1 (insulin-dependent) diabetes mellitus. Lancet II: 1363–1365CrossRefGoogle Scholar
  22. 22.
    Pujoll-Borell R, Hanafusa T, Cudworth AG, Bottazzo GF (1982) Islet-cell surface antibodies and the natural history of Type 1 (insulin-dependent) diabetes. Diabetologia 23:194AGoogle Scholar
  23. 23.
    Baekkeskov S, Braining J, Srikanta S, Mandrup-Poulsen T, de Beaufort C, Eisenbarth G, Nerup J, Lemmark Å (1986) Antibodies to a Mr 64,000 human islet cell protein in the prediabetic period of IDDM patients. Ann NY Acad Sci 475: 415–417CrossRefGoogle Scholar
  24. 24.
    Srikanta S, Ricker T, McCulloch DK, Soeldner JS, Eisenbarth GS, Palmer JP (1986) Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 35:139–142PubMedCrossRefGoogle Scholar
  25. 25.
    Marner B, Agner T, Binder C, Lemmark Å, Nerup J, Mandrup-Poulsen T, Waldorff S (1985) Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients. Diabetologia 28: 875–880PubMedCrossRefGoogle Scholar
  26. 26.
    Bottazzo GF, Dean BM, Gorsuch AN, Cudworth AG, Doniach D (1980) Complement-fixing islet-cell antibodies in type-I diabetes: possible monitors of active beta-cell damage. Lancet I: 668–672Google Scholar
  27. 27.
    Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS (1983) Islet-cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for type 1 diabetes mellitus. N Engl J Med 308:322–325PubMedCrossRefGoogle Scholar
  28. 28.
    Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS (1985) First-degree relatives of patients with type 1 diabetes mellitus. Islet cell antibodies and abnormal insulin secretion. N Engl J Med 313:461–464PubMedCrossRefGoogle Scholar
  29. 29.
    Rittenhouse HG, Oxender DL, Pek S, Ar D (1980) Complement-mediated cytotoxic effects on pancreatic islets with sera from diabetic patients. Diabetes 317–322Google Scholar
  30. 30.
    Dobersen MJ, Scharff JE, Ginsberg-Fellner F, Notkins AL (1980) Cytotoxic autoantibodies to beta cells in the serum of patients with insulin-dependent diabetes mellitus. N Engl J Med 303:1493–1498PubMedCrossRefGoogle Scholar
  31. 31.
    Sai P, Boitard C, Debray-Sachs M, Pouplard A, Assan R, Hamburger J (1981) Complement-fixing islet cell antibodies from some diabetic patients alter insulin release in vitro. Diabetes 30: 1051–1057PubMedCrossRefGoogle Scholar
  32. 32.
    Kanatsuna T, Lemmark Å, Rubinstein AH, Steiner DF (1981) Block in insulin release from column-perifused pancreatic beta-cells induced by islet cell surface antibodies and complement. Diabetes 30: 231–234PubMedCrossRefGoogle Scholar
  33. 33.
    Kanatsuna T, Baekkeskov S, Lemmark Å, Ludvigsson J (1983) Immunoglobulin from insulin-dependent diabetic children inhibits glucose-induced insulin release. Diabetes 32: 520–524PubMedCrossRefGoogle Scholar
  34. 34.
    Svenningsen A, Dyrberg T, Gerlin I, Lemmark Å, MacKay P, Rabinovitch A (1983) Inhibition of insulin release after passive transfer of immunoglobulin from insulin-dependent diabetic children to mice. J Clin Endocrinol Metab 57:1301–1304PubMedCrossRefGoogle Scholar
  35. 35.
    Spencer KM, Tarn A, Dean BM, Lister J, Bottazzo GF (1984) Fluctuating islet-cell autoimmunity in unaffected relatives of patients with insulin-dependent diabetes. Lancet I: 764–766CrossRefGoogle Scholar
  36. 36.
    Srikanta S, Ganda OP, Jackson RA, Brink SJ, Fleischnick E, Yunis E, Alper C, Soeldner JS, Eisenbarth GS (1984) Pre-type 1 (insulin-dependent) diabetes: common endocrinological course despite immunological and immunogenetic heterogeneity. Diabetologia 27: 146–148PubMedCrossRefGoogle Scholar
  37. 37.
    Tingle AJ, Lim G, Wright VJ, Dimmick JF, Hunt JA (1979) Transplacental passage of islet cell antibodies in infants of diabetic mothers. Pediatr Res 13:1323–1325PubMedCrossRefGoogle Scholar
  38. 38.
    Mandrup-Poulsen T, Nerup J, Stiller CR, Marner B, Bille G, Heinrichs D, Martell R, Dupre J, Keown PA, Jenner MR, Rodger NW, Wolfe B, Graffenried BV, Binder C (1985) Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet I: 599–602CrossRefGoogle Scholar
  39. 39.
    Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Charbonnel B, Rodier M, Lallemand A, Bach J-F (1986) Cyclosporine A in recent onset type 1 (insulin-dependent) diabetic patients: preliminary analysis of the French randomized trial at 6–9 months. Diabetologia 29: 536AGoogle Scholar
  40. 40.
    Charles MA, Suzuki M, Waldeck N, Dodson LE, Slater L, Ong K, Kershnar A, Buckingham B, Golden M (1983) Immune islet killing mechanisms associated with insulin-dependent diabetes: in vitro expression of cellular and antibody-mediated islet cell cytotoxicity in humans. J Immunol 130:1189–1195PubMedGoogle Scholar
  41. 41.
    Lohmann D, Krug J, Lampeter EF, Bierwolf B, Verlohren H-J (1986) Cell-mediated immune reactions against B cells and defect of suppressor cell activity in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 29: 421–425PubMedCrossRefGoogle Scholar
  42. 42.
    Boitard C, Debray-Sachs M, Pouplard A, Assan R, Hamburger J (1981) Lymphocytes from diabetics suppress insulin release in vitro. Diabetologia 21: 41–46PubMedGoogle Scholar
  43. 43.
    Quiniou-Debrie MC, Debray-Sachs M, Dardenne M, Czernichow P, Assan R, Bach JF (1985) Anti-islet cellular and humoral immunity, T-cell subsets, and thymic function in type 1 diabetes. Diabetes 34: 373–379PubMedCrossRefGoogle Scholar
  44. 44.
    Boitard C, Chatenoud L-M, Debray-Sachs M (1982) In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon. J Immunol 129: 2529–2531PubMedGoogle Scholar
  45. 45.
    Negishi K, Waldeck N, Chandy G, Buckingham B, Kershnar A, Fisher L, Gupta S, Charles MA (1986) Natural killer cell and islet killer cell activities in type 1 (insulin-dependent) diabetes. Diabetologia 29: 352–357PubMedCrossRefGoogle Scholar
  46. 46.
    Weringer EJ, Like AA (1985) Immune attack on pancreatic islet transplants in the spontaneously diabetic Biobreeding/Worcester (BB/W) rat is not MHC restricted. J Immunol 134: 2384–2386Google Scholar
  47. 47.
    Prowse SJ, Bellgrau D, Lafferty KJ (1986) Islet allografts are destroyed by disease occurrence in the spontaneously diabetic BB rat. Diabetes 35:110–114PubMedCrossRefGoogle Scholar
  48. 48.
    Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ (1986) Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35: 1302–1304PubMedCrossRefGoogle Scholar
  49. 49.
    Lanier LL, Phillips JH (1986) Evidence for three types of human cytotoxic lymphocytes. Immunol Today 7:132–134CrossRefGoogle Scholar
  50. 50.
    Yanagi Y, Caccia N, Kronenberg M, Chin B, Roder J, Rohel D, Kiyohara, Lauzon R, Toyonaga B, Rosenthal K, Dennert G, Acha-Orbea H, Hengartner H, Hood L, Mak TW (1985) Gene rearrangement in cells with natural killer activity and expression of the beta-chain of the T-cell antigen receptor. Nature 314: 631–633PubMedCrossRefGoogle Scholar
  51. 51.
    Moingeon P, Ythier A, Goubin G, Faure F, Nowill A, Delmon L, Rainaud M, Forestier F, Daffos F, Bohuon C, Hercend T (1986) A unique T-cell receptor complex expressed on human fetal lymphocytes displaying natural-killer-like activity. Nature 323: 638–640PubMedCrossRefGoogle Scholar
  52. 52.
    Woda BA, Biron CA (1986) Natural killer cell number and function in the spontaneously diabetic BB/W rat. J Immunol 137:1860–1866PubMedGoogle Scholar
  53. 53.
    MacKay P, Jacobson J, Rabinovitch A (1986) Spontaneous diabetes mellitus in the BioBreeding/Worcester rat. Evidence in vitro for natural killer cell lysis of islet cells. J Clin Invest 77: 916–924PubMedCrossRefGoogle Scholar
  54. 54.
    Like AA, Biron CA, Weringer EJ, Byman K, Sroczynski E, Guberski DL (1986) Prevention of diabetes in Biobreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med 164:1145–1159PubMedCrossRefGoogle Scholar
  55. 55.
    Debray-Sachs M, Boitard C, Assan R, Hamburger J (1981) Are “activated” macrophages cytotoxic against normal cells? Transplant Proc 13:1111–1113PubMedGoogle Scholar
  56. 56.
    Schwitzer RW, Leiter EH, Evans R (1984) Macrophage-mediated cytotoxicity against cultured pancreatic islet cells. Transplantation 37: 539–544CrossRefGoogle Scholar
  57. 57.
    Oschilewski U, Kiesel U, Kolb H (1985) Administration of silica prevents diabetes in BB rats. Diabetes 34:197–199PubMedCrossRefGoogle Scholar
  58. 58.
    Nash JR, Everson NW, Wood RFM, Bell PRF (1980) Effect of silica and carrageenan on the survival of islet allografts. Transplantation 29: 206–208PubMedCrossRefGoogle Scholar
  59. 59.
    Scala G, Allavena P, Djeu JY, Kasahara T, Ortaldo JR, Herberman RB, Oppenheim JJ (1984) Human large granular lymphocytes are potent producers of interleukin-1. Nature 309: 56–59PubMedCrossRefGoogle Scholar
  60. 60.
    Bendtzen K (1985) Lymphokines in inflammation. In: Venge P, Lindbom A (eds) Inflammation — basic mechanisms, tissue injuring principles, and clinical models. Almqvist and Wiksell, Stockholm, pp 187–217Google Scholar
  61. 61.
    Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J (1985) Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 40: 424–429PubMedCrossRefGoogle Scholar
  62. 62.
    Mandrup-Poulsen T, Bendtzen K, Nerup J, Egeberg J, Nielsen JH (1986) Mechanisms of pancreatic islet cell destruction. Dose-dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy 41: 250–259PubMedCrossRefGoogle Scholar
  63. 63.
    Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH (1986) Affinity-purified human interleukin 1 is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63–67PubMedCrossRefGoogle Scholar
  64. 64.
    Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M (1986) Cytotoxicity of human pI7 interleukin-1 for pancreatic islets of Langerhans. Science 232: 1545–1547PubMedCrossRefGoogle Scholar
  65. 65.
    Bendtzen K, Barington T, Mandrup-Poulsen T, Pedersen JG, Svenson M (1986) Measurement of human IL-1 by LIF induction, pancreatic islet-cell cytotoxicity, and bone resorption. Lymphogne Res 5: S93–S98Google Scholar
  66. 66.
    Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, Dinarello CA (1987) Ultrastructural study of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. Acta Pathol Microbiol Immunol Scand (C) Acta path, microbiol. immunol. scand. Sect C, 95:55–63Google Scholar
  67. 67.
    Dinarello CA (1984) Interleukin-1. Rev Infect Dis 6: 51–95CrossRefGoogle Scholar
  68. 68.
    Dinarello CA (1984) Interleukin-1 and the acute-phase response. N Engl J Med 311: 1413–1418PubMedCrossRefGoogle Scholar
  69. 69.
    Dinarello CA (1986) Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (Cachectin). In: Cruse JM, Lewis RE, Jackson M (eds) The year in immunology, vol 2. Karger, Basel, pp 68–89Google Scholar
  70. 70.
    Klempner MS, Dinarello CA, Henderson WR, Gallin JI (1979) Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest 64: 996–1002PubMedCrossRefGoogle Scholar
  71. 71.
    Matsubara T, Ziff M (1986) Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 137: 3295–3298PubMedGoogle Scholar
  72. 72.
    Malaisse WJ (1982) Alloxan toxicity to the pancreatic B-cell. A new hypothesis. Biochem Pharmacol 31:3527–3534PubMedCrossRefGoogle Scholar
  73. 73.
    Svejgaard A, Jakobsen BK, Platz P, Ryder LP, Nerup J, Christy M, Borch-Johnsen K, Parving H-H, Deckert T, Mølsted-Pedersen L, Kühl C, Buschard K, Green A (1986) HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous population. Tissue Antigens 28: 237–244PubMedCrossRefGoogle Scholar
  74. 74.
    Nerup J (1974) The clinical and immunological association of diabetes mellitus and Addison’s disease. In: Bastenie PA, Gepts W (eds) Immunity and autoimmunity in diabetes mellitus. Excerpta Medica, Amsterdam, pp 149–152Google Scholar
  75. 75.
    Nerup J, Mandrup-Poulsen T, Molvig J (1987) The HLA-IDDM association: implications for etiology and pathogenesis of IDDM. In: De Fronzo RA, Skylev JS (eds) Diabetes/Metabolism Rev 3: 779–802Google Scholar
  76. 76.
    Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL (1986) Genes for the tumor necrosis factors α and ß are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83: 8699–8702PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. Nerup
  • T. Mandrup-PouIsen
  • J. Mølvig
  • G. Spinas

There are no affiliations available

Personalised recommendations